<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35923425</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trial.</ArticleTitle><Pagination><StartPage>101596</StartPage><MedlinePgn>101596</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101596</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2022.101596</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The enterovirus 71 (EV71) vaccine produced by Wuhan Institute of Biological Products Co., Ltd. (WIBP) (B-EV71) has been given to children aged 6-35 months, and it has shown good safety, immunogenicity and efficacy. However, the administration of EV71 vaccine in children aged 36-71 months, which is another target population, needs further exploration.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a double-blind, randomised, controlled, non-inferiority phase III clinical trial in children aged 36-71 months, with a further comparison group of children aged 6-35 months in China. Children aged 6-71 months with no history of hand, foot and mouth disease or prior-vaccination of EV71 vaccine were eligible and recruited. Eligible participants aged 36-71 months were randomly assigned (1:1) to receive two doses of the B-EV71 vaccine (Older-B group) or the control EV71 vaccine (C-EV71 vaccine, produced by Institute of Medical Biology, Chinese Academy of Medical Sciences) (Older-C group), administered at a 30-day interval. Eligible participants aged 6-35 months were enrolled consecutively to receive two doses of the B-EV71 vaccine (Younger-B group) at a 30-day interval. Participants, investigators and those assessing outcomes were masked to the vaccine received. Non-inferiority analyses were conducted to compare the immunogenicity of EV71 vaccine in the Older-B group with that in the Older-C and Younger-B groups. Non-inferiority margins were 10% for seroconversion rate differences and 0.5 for geometric mean titre (GMT) ratios. The primary endpoints were the GMT level and seroconversion rate of anti-EV71 neutralising antibody 30 days after the second dose of vaccination. The primary analysis was performed in the per-protocol population. Safety analyses were conducted amongst participants receiving at least one dose of vaccine. This trial was registered at Chinadrugtrials.org.cn (#CTR20192345).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Between June 3 and June 30, 2020, 1600 participants were enrolled and assigned, including 625 participants in the Older-B group, 625 participants in the Older-C group and 350 participants in the Younger-B group. The seroconversion rate of anti-EV71 neutralising antibody in the Older-B group (99.66%; 95% CI: 99.18%-100.00%) was non-inferior to that of the Older-C (99.32%; 95% CI: 98.65%-99.98%) and Younger-B groups (100.00%; 95% CI: 100.00%-100.00%). The differences in seroconversion rates in the Older-B group to those in the Older-C and Younger-B groups were 0.34% (95%CI: -2.17%-2.86%) and -0.34% (95%CI: -2.78%-2.09%). The GMT of the anti-EV71 neutralising antibody in the Older-B group (693.87) was also non-inferior to that in the Older-C (289.37) and Younger-B groups (634.80). The ratios of GMTs in the Older-B group to those in the Older-C and Younger-B groups were 2.67 (95%CI: 2.00-3.00) and 1.00 (95%CI: 0.75-1.00), respectively. The incidence of any adverse event (AE) related to vaccination was similar amongst the three groups (34/625 [5.44%] in the Older-B group, 32/623 [5.14%] in the Older-C group, and 26/349 [7.45%] in the Younger-B group), with only 2 (0.57%) participants having grade 3 AEs in the Younger-B group. Fifteen (0.94%) participants from these three groups had reported serious AEs (SAEs), all of which were unrelated to vaccines.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">EV71 vaccine produced by WIBP could extend to be administered to children aged 36-71 months against EV71 infection. However, the persistence of vaccine-induced immunities needs to be further investigated.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Hubei Province's young medical talent program (20191229), Hubei Province's young talent program (2021), Hubei Province's young public health talent program (2021); and the Wuhan Institute of Biological Products Co., Ltd.</AbstractText><CopyrightInformation>&#xa9; 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Yeqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xinyue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jinhua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Beifang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Xiaoai</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiahong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Xiangzhou District Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hang</LastName><ForeName>Lianju</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Xiangzhou District Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Shaoyong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Xiangzhou District Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinguo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Changfu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Heng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tingbo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qingliang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Hongqiao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Vaccine &amp;Serum Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Xuhua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Biological Products Co., Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoqi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus 71 vaccine</Keyword><Keyword MajorTopicYN="N">Hand, foot and mouth disease</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList><CoiStatement>YT reported receiving grants from Hubei Province's young medical talent program (20191229), Hubei Province's young talent program (2021), and Hubei Province's young public health talent program (2021) during the conduct of the study. JC, WC, KD, XL, CG, TX, QLL, LL, HD, and XC report being employees of Wuhan Institute of Biological Products Co Ltd. All other authors report no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>2</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35923425</ArticleId><ArticleId IdType="pmc">PMC9340505</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2022.101596</ArticleId><ArticleId IdType="pii">S2589-5370(22)00326-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XW, Ni X, Qian SY, et al. Chinese guidelines for the diagnosis and treatment of hand, foot and mouth disease (2018 edition) World J Pediatr. 2018;14(5):437&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">30280313</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129(3):304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Spence-Davizon E, Osborne C, et al. Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study. Lancet Infect Dis. 2020;20(2):230&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11284833</ArticleId><ArticleId IdType="pubmed">31859216</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Huang Y, Zhu D, Yang S, Hu D. Risk factors for severe hand-foot-mouth disease in China: a systematic review and meta-analysis. Front Pediatr. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631475</ArticleId><ArticleId IdType="pubmed">34858899</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . World Health Organization; Geneva, Switzerland: 2011. A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD)https://apps.who.int/iris/handle/10665/207490 Accessed 28 September 2012.</Citation></Reference><Reference><Citation>Wang XL, Wei HX, Jia L, Huo D, Wang HQ, Wang QY. [Summary of research in economic burden of hand, foot, and mouth disease in China] Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):273&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">32164141</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZL, Xia AM, Li YF, et al. Socioeconomic burden of hand, foot and mouth disease in children in Shanghai, China. Epidemiol Infect. 2016;144(1):138&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9507314</ArticleId><ArticleId IdType="pubmed">26159305</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan ZK, Jin H, Li JX, et al. Disease burden of enterovirus 71 in rural central China: a community-based survey. Hum Vaccines Immunother. 2015;11(10):2400&#x2013;2405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4635911</ArticleId><ArticleId IdType="pubmed">26158689</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Jit M, Wu JT, et al. Economic costs and health-related quality of life for hand, foot and mouth disease (HFMD) patients in China. PLoS One. 2017;12(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5608208</ArticleId><ArticleId IdType="pubmed">28934232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J. [Trend of epidemics and variation of pathogens of hand, foot and mouth disease in China: a dynamic series analysis, 2008-2017] Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40(2):147&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">30744263</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong S, Ren X, Zhang C, et al. Morbidity analysis of the notifiable infectious diseases in China, 2018. China CDC Wkly. 2019;1(4):47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422198</ArticleId><ArticleId IdType="pubmed">34594603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024&#x2013;2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev Vaccines. 2016;15(7):803&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206811</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Wu P, Wu JT, et al. Seroprevalence of enterovirus 71 antibody among children in China: a systematic review and meta-analysis. Pediatr Infect Dis J. 2015;34(12):1399&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718881</ArticleId><ArticleId IdType="pubmed">26368058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Liu F, Liao Q, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017;22(50):16&#x2013;00824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Yin H, An Z, Feng Z. Considerations for developing an immunization strategy with enterovirus 71 vaccine. Vaccine. 2015;33(9):1107&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">25444807</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang CY, Liu CC. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vaccines. 2018;17(9):819&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Zhang M, Zhao C, Zheng P, Zhang X, Xu J. From monovalent to multivalent vaccines, the exploration for potential preventive strategies against Hand, Foot, and Mouth Disease (HFMD) Virol Sin. 2021;36(2):167&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525078</ArticleId><ArticleId IdType="pubmed">32997323</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan X, Che Y, Wei S, et al. Effectiveness and safety of an inactivated enterovirus 71 vaccine in children aged 6-71 months in a phase iv study. Clin Infect Dis. 2020;71(9):2421&#x2013;2427.</Citation><ArticleIdList><ArticleId IdType="pubmed">31734699</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao Q, et al. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011;29(52):9668&#x2013;9674.</Citation><ArticleIdList><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, Meng F, Wang S, et al. 2-Year efficacy, immunogenicity, and safety of Vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215(1):56&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Jin P, Li JX, Zhu FC, Liu P. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints. Expert Rev Vaccines. 2017;16(9):945&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">28548626</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Jin P, Chen X, et al. Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial. Hum Vaccines Immunother. 2022;18(5) doi: 10.1080/21645515.2022.206363. [Published online ahead of print, 2022 Jun 17]</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.206363</ArticleId><ArticleId IdType="pmc">PMC9897631</ArticleId><ArticleId IdType="pubmed">35714273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Gao F, Zeng G, et al. Immunogenicity and safety of inactivated enterovirus 71 vaccine in children aged 36-71 months: a double-blind, randomized, controlled, non-inferiority phase III trial. J Pediatr Infect Dis Soc. 2021;10(4):440&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">33269798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>